Teriflunomide ( Aubagio ) is an immunomodulatory drug inhibiting pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase. Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in multiple sclerosis.
The FDA ( Food and Drug Administration ) has approved Aubagio, a once-a-day tablet, for the treatment of adults with relapsing forms of multiple sclerosis
Important safety information
A patient should not take Aubagio if it has severe liver problems. Aubagio may cause serious liver problems, which can be life-threatening.
The risk may be higher if it takes other medicines that affect the liver.
The physician should do blood tests to check the patients liver within 6 months before it starts taking Aubagio and once a month for 6 months after it starts taking Aubagio.
The patient should call the doctor right away if it develops any of these symptoms of liver problems: nausea, vomiting, stomach pain, loss of appetite, tiredness, yellowing of skin or whites of eyes, or dark urine.
The patient should not take Aubagio if it takes a medicine called Leflunomide ( Arava ).
Aubagio can be harmful to the fetus. The patient should not take Aubagio if it is pregnant or is of childbearing age and not using effective birth control.